Liquid Biopsy Market

Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-Cancer), End User (Reference Lab, Hospitals) - Global Forecast to 2026

Report Code: MD 4456 Nov, 2021, by marketsandmarkets.com

[231 Pages Report] The global liquid biopsy market is projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 18.1% during the forecast period. Market is driven by the rising incidence and prevalence of cancer and the increasing preference for noninvasive treatment procedures.

Liquid Biopsy Market

To know about the assumptions considered for the study, Request for Free Sample Report

OVID-19 Impact on Global Liquid Biopsy Market

The unprecedented impact of COVID-19 has been far-reaching, but the effects on cancer patients make them one of the worst affected groups. COVID-19 has profoundly impacted the number of patients undergoing cancer screening, diagnosis, and treatment. The increased pressure due to the growing rate of COVID-19 patients' hospitalization led to the re-profiling of many hospitals and departments, including oncology clinics for treating patients with the COVID-19. Consequently, according to one study, many diagnostic and treatment procedures had been canceled or postponed around the world, including as many as 2.3 million cancer surgeries.

However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to growing cancer incidence has become a pressing medical issue worldwide. Several patients affected with COVID-19 were people with malignancies, due to which cancer has been identified as a risk factor for COVID-19. Research in this area is further undertaken to better understand the infection dynamics, which is expected to propel the cancer research field further. This is further expected to drive the demand for liquid biopsy products.

Market Dynamics

Driver: Rising incidence and prevalence of cancer

Globally, there has been a significant increase in the number of people who have cancer. The rising prevalence of cancer can be attributed to several factors, such as environmental factors, tobacco consumption, infectious agents such as Hepatitis B and C, and lifestyle changes. According to the WHO, cancer is the second-leading cause of death globally. International Agency for Research on Cancer (IARC) estimated the global cancer burden, indicating that it has risen to 19.3 million cases and 9.96 million cancer deaths in 2020. Liquid biopsy holds several benefits over traditional cancer diagnostics techniques—reduced cost, early prognosis, therapy monitoring, detection of tumor heterogeneity, acquired drug resistance, and patient comfort (by eliminating the need for surgery). As a result, the preference for liquid biopsy will likely rise in the forecast period, proportional to the growth in cancer prevalence.

Restraint: The lower sensitivity of certain liquid biopsies

Detecting ctDNA in liquid biopsies is technically challenging because the levels of ctDNA of any given cancer mutation may be very low in the plasma of a cancer patient, especially after treatment or surgery. The sampling statistics mean that in any individual sample of plasma from a patient, there may be less than one detectable copy of the ctDNA with the cancer mutation. This may result in the ctDNA not being detected in the patient sample, even though it is present in the plasma, but at a low level. This leads to false-negative results in which ctDNA is not detected even though it is present and impacts the informative value of the liquid biopsy tests for cancer. In some cases, false negatives may mean that the recurrence of a tumor is not detected at an early stage.

Opportunity: The growing significance of companion diagnostics

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products can significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With the increased demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics has high growth potential. The growing importance of companion diagnostics is also providing growth opportunities for the liquid biopsy market.

Challenge: Unclear reimbursement scenario

The process of paying for expensive molecular tests and the expertise of the multiple professionals required to interpret test results and formulate treatment plans are inconsistent and complex. This is especially an issue with newer technologies such as liquid biopsy, with higher price tags. Physicians, pathologists, and patients often do not know the costs of molecular testing services until they are reimbursed or billed. The confusion is distressing for both patients and providers.

Payers also structure their policies for biomarker coverage in multiple ways, making them difficult to understand. While some reimburse for many types of tests, others reimburse for only the most basic tests or specific clinical conditions and genes. This wide variation often increases the challenge of assessing and tracking numerous coverage policies.

“In 2020, assay kits segment accounted for the largest share of the liquid biopsy market, by product & service”

The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. The assay kits segment accounted for the largest share of the liquid biopsy market in 2020. The standard purchase requirement of assay kits makes them a recurrent cost which is a key factor attributing to the growth of this segment.

“In 2020, cancer application segment accounted for the largest share in the market, by application”

The liquid biopsy market is segmented into cancer and non-cancer applications based on application. The cancer application segment accounted for the largest share of the liquid biopsy market in 2020. Factors such as the increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications are driving the growth of this segment.

“In 2020, reference laboratories segment accounted for the largest share in the market, by end user”

The liquid biopsy market has been segmented into reference laboratories, hospitals and physician laboratories, academic & research centers, and other end users. The reference laboratories segment accounted for the largest share of the liquid biopsy market in 2020. The increasing outsourcing of liquid biopsy tests to reference laboratories is driving the growth of this segment.

“North America is the largest regional market for liquid biopsy”

The global liquid biopsy market has been segmented into four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. In 2020, North America accounted for the largest share of the liquid biopsy market. The large share of this regional segment can be attributed to the easy accessibility to technologically advanced instruments, highly developed healthcare systems in the US and Canada, and presence of many leading national clinical laboratories.

Liquid Biopsy Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some Key Players in the Liquid Biopsy Market (2021- 2026)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Product & service, circulating biomarkers, technology, application, clinical application, end user, and region

Geographies covered

North America, Europe, Asia Pacific, and the Rest of the World

Companies covered

F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Guardant Health, Inc. (US), MDxHealth SA (Belgium), Exact Sciences Corporation (US), Illumina Inc. (US), Sysmex Inostics (US), Bio-Rad Laboratories, Inc. (US), Biocept, Inc. (US), NeoGenomics, Inc. (US), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences, Inc. (US), Exosome Diagnostics, Inc. (US), Agena Bioscience, Inc. (US), MedGenome Inc. (US), Epigenomics AG (Germany), and Personal Genome Diagnostics, Inc. (US).

This report categorizes the liquid biopsy market into the following segments and subsegments:

By Product & Service

  • Assay Kits
  • Instruments
  • Services

By Circulating Biomarkers

  • Circulating Tumor Cells
  • Circulating Tumor DNA (ctDNA)
  • Cell-free DNA (cfDNA)
  • Extracellular Vesicles (EVS)
  • Other Circulating Biomarkers

By Application

  • Cancer Application
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Melanoma
    • Other Cancers
  • Non-cancer Applications

By Technology

  • Multi-gene Parallel Analysis using NGS
  • Single-gene Analysis using PCR Microarrays

By Clinical Application

  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring

By End User

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic & Research Centers
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments

  • In June 2021, Guardant Health, Inc. (US) launched its Guardant360 Response test that detects changes in circulating tumor DNA (ctDNA) levels.
  • In October 2020, F. Hoffmann-La Roche Ltd. (Switzerland) received the US FDA approval of expanded claims for the cobas EGFR Mutation Test v2 to be used as a companion diagnostic (CDx) for a broader group of therapies to treat non-small cell lung cancer (NSCLC).
  • In March 2020, Biocept, Inc. (US) entered into an agreement with a second California-based independent physician association (IPA) to provide its Target Selector liquid biopsy assay services to physicians and patients in the network.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 29)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
           1.2.2 MARKETS COVERED
                    FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LIQUID BIOPSY MARKET)
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                               FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast (2021-2026)
                    2.3.1.4 CAGR projections
                               FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE
    2.6 ASSUMPTIONS FOR THE STUDY
    2.7 LIMITATIONS
    2.8 RISK ASSESSMENT
           2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET
    2.9 GROWTH RATE ASSUMPTIONS
    2.10 COVID-19 HEALTH ASSESSMENT
    2.11 COVID-19 ECONOMIC ASSESSMENT
    2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
                    FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
                    FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
    2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET

3 EXECUTIVE SUMMARY (Page No. - 51)
    FIGURE 11 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 LIQUID BIOPSY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 16 LIQUID BIOPSY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 56)
    4.1 LIQUID BIOPSY MARKET OVERVIEW
           FIGURE 18 THE RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE LIQUID BIOPSY MARKET
    4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
           FIGURE 19 THE ASSAY KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
    4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKERS, 2021 VS. 2026
           FIGURE 20 THE CIRCULATING TUMOR CELLS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
    4.4 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
           FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
    4.5 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2021 VS. 2026
           FIGURE 22 CANCER APPLICATIONS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
    4.6 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2021 VS. 2026
           FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.7 LIQUID BIOPSY MARKET SHARE, BY END USER, 2021 VS. 2026
           FIGURE 24 REFERENCE LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
    4.8 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 25 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE LIQUID BIOPSY MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 61)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 26 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence and prevalence of cancer
                               TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
                    5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
                    5.2.1.3 Increasing preference for noninvasive treatment procedures
           5.2.2 RESTRAINTS
                    5.2.2.1 The lower sensitivity of certain liquid biopsies
           5.2.3 OPPORTUNITIES
                    5.2.3.1 The growing significance of companion diagnostics
                    5.2.3.2 Growth opportunities in emerging countries
           5.2.4 CHALLENGES
                    5.2.4.1 Unclear reimbursement scenario
    5.3 IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET
    5.4 REALISTIC, PESSIMISTIC, AND OPTIMISTIC SCENARIOS
           5.4.1 LIQUID BIOPSY MARKET
                    FIGURE 27 REALISTIC SCENARIO
                    FIGURE 28 PESSIMISTIC SCENARIO
                    FIGURE 29 OPTIMISTIC SCENARIO
    5.5 PRICING ANALYSIS
           TABLE 2 PRICE OF LIQUID BIOPSY PRODUCTS (2021)
    5.6 PATENT ANALYSIS
           5.6.1 PATENT ANALYSIS OF CIRCULATING BIOMARKERS
    5.7 VALUE CHAIN ANALYSIS
           FIGURE 30 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
           FIGURE 31 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.8 ECOSYSTEM ANALYSIS OF THE LIQUID BIOPSY MARKET
           FIGURE 32 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
    5.9 PORTER’S FIVE FORCES ANALYSIS
           TABLE 3 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 THREAT OF NEW ENTRANTS
           5.9.2 THREAT OF SUBSTITUTES
           5.9.3 BARGAINING POWER OF BUYERS
           5.9.4 BARGAINING POWER OF SUPPLIERS
           5.9.5 DEGREE OF COMPETITION
    5.10 REGULATORY LANDSCAPE
           5.10.1 NORTH AMERICA
                    5.10.1.1 US
                    5.10.1.2 Canada
           5.10.2 EUROPE
           5.10.3 ASIA PACIFIC
                    5.10.3.1 China
                    5.10.3.2 Japan
           5.10.4 LATIN AMERICA
                    5.10.4.1 Brazil
                    5.10.4.2 Mexico
           5.10.5 MIDDLE EAST
           5.10.6 AFRICA
    5.11 TECHNOLOGY ANALYSIS
    5.12 PESTLE ANALYSIS
    5.13 TRADE ANALYSIS
           5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    5.13.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million)
                    5.13.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons)
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
           5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
           5.14.2 REVENUE SHIFT FOR THE LIQUID BIOPSY MARKET

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE (Page No. - 81)
    6.1 INTRODUCTION
           TABLE 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
    6.2 ASSAY KITS
           6.2.1 REPEATED REQUIREMENT PURCHASES OF ASSAY KITS TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 5 KEY PRODUCTS IN THE ASSAY KITS MARKET
                    TABLE 6 LIQUID BIOPSY MARKET FOR ASSAY KITS, BY REGION, 2019–2026 (USD MILLION)
    6.3 INSTRUMENTS
           6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH OF THIS SEGMENT
                    TABLE 7 KEY PRODUCTS IN THE INSTRUMENTS MARKET
                    TABLE 8 LIQUID BIOPSY MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
    6.4 SERVICES
           6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT THE MARKET GROWTH
                    TABLE 9 LIQUID BIOPSY MARKET FOR SERVICES, BY REGION, 2019–2026 (USD MILLION)

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS (Page No. - 87)
    7.1 INTRODUCTION
           7.1.1 PRIMARY NOTES
                    7.1.1.1 Key industry insights
                               TABLE 10 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
    7.2 CIRCULATING TUMOR CELLS (CTC)
           7.2.1 BENEFITS OF EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF THE OVERALL TUMOR BURDEN TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 11 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2019–2026 (USD MILLION)
    7.3 CIRCULATING TUMOR DNA (CTDNA)
           7.3.1 CTDNA ANALYSIS CAN SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS, THUS LEADING TO EARLY-STAGE DETECTION OF CANCER
                    TABLE 12 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2019–2026 (USD MILLION)
    7.4 CELL-FREE DNA (CFDNA)
           7.4.1 APPLICATION OF CFDNA IN PRENATAL SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 13 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2019–2026 (USD MILLION)
    7.5 EXTRACELLULAR VESICLES (EVS)
           7.5.1 EVS ARE STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES, THUS ENSURING THE GROWTH OF THIS SEGMENT
                    TABLE 14 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2019–2026 (USD MILLION)
    7.6 OTHER CIRCULATING BIOMARKERS
           TABLE 15 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2019–2026 (USD MILLION)

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY (Page No. - 94)
    8.1 INTRODUCTION
           8.1.1 PRIMARY NOTES
                    8.1.1.1 Key industry insights
                               TABLE 16 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
           8.2.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 17 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, 2019–2026 (USD MILLION)
    8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
           8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 18 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, 2019–2026 (USD MILLION)

9 LIQUID BIOPSY MARKET, BY APPLICATION (Page No. - 97)
    9.1 INTRODUCTION
           TABLE 19 LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    9.2 CANCER APPLICATIONS
           TABLE 20 CANCER INCIDENCE, BY REGION, 2020 VS. 2040 (MILLION)
           TABLE 21 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 22 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           9.2.1 LUNG CANCER
                    9.2.1.1 Increasing prevalence of lung cancer to propel the market growth
                               TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                               TABLE 24 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
           9.2.2 BREAST CANCER
                    9.2.2.1 Increasing government funding for breast cancer research is expected to drive the market growth
                               TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                               TABLE 26 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
           9.2.3 COLORECTAL CANCER
                    9.2.3.1 Increasing prevalence of colorectal cancer to propel the market growth
                               TABLE 27 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                               TABLE 28 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION,  2019–2026 (USD MILLION)
           9.2.4 PROSTATE CANCER
                    9.2.4.1 Growing number of prostate cancer patients to drive the growth of this market
                               TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                               TABLE 30 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2026 (USD MILLION)
           9.2.5 MELANOMA
                    9.2.5.1 Increasing need for the early diagnosis of genetically mutated tumors to drive market growth
                               TABLE 31 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
                               TABLE 32 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2019–2026 (USD MILLION)
           9.2.6 OTHER CANCERS
                    TABLE 33 GLOBAL CANCER INCIDENCE, 2020
                    TABLE 34 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
    9.3 NON-CANCER APPLICATIONS
           9.3.1 APPLICATIONS OF LIQUID BIOPSY FOR NIPT AND ORGAN TRANSPLANTATION DIAGNOSIS DRIVES THE GROWTH OF THIS SEGMENT
                    TABLE 35 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION (Page No. - 110)
     10.1 INTRODUCTION
               TABLE 36 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
     10.2 THERAPY SELECTION
             10.2.1 INCREASING PREFERENCE DUE TO NONINVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS SEGMENT
                       TABLE 37 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2019–2026 (USD MILLION)
     10.3 TREATMENT MONITORING
             10.3.1 LIQUID BIOPSY FOR TREATMENT MONITORING QUANTITATIVELY CALCULATES THE CONCENTRATION OF CANCER-RELATED MUTATIONS
                       TABLE 38 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2019–2026 (USD MILLION)
     10.4 RECURRENCE MONITORING
             10.4.1 THE ABILITY TO DETECT CANCER MUTATION THROUGH CTDNA IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
                       TABLE 39 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2019–2026 (USD MILLION)
     10.5 EARLY CANCER SCREENING
             10.5.1 POTENTIAL OF LIQUID BIOPSY IN THE DETECTION OF CANCER AT EARLY STAGES TO DRIVE MARKET GROWTH
                       TABLE 40 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2019–2026 (USD MILLION)

11 LIQUID BIOPSY MARKET, BY END USER (Page No. - 116)
     11.1 INTRODUCTION
               TABLE 41 LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.2 REFERENCE LABORATORIES
             11.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES DRIVES THE GROWTH OF THIS SEGMENT
                       TABLE 42 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
     11.3 HOSPITALS AND PHYSICIAN LABORATORIES
             11.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING THE GROWTH OF THIS SEGMENT
                       TABLE 43 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
     11.4 ACADEMIC & RESEARCH CENTERS
             11.4.1 GROWING FOCUS OF RESEARCH IN THE DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
                       TABLE 44 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2019–2026 (USD MILLION)
     11.5 OTHER END USERS
               TABLE 45 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)

12 LIQUID BIOPSY MARKET, BY REGION (Page No. - 121)
     12.1 INTRODUCTION
               TABLE 46 LIQUID BIOPSY MARKET, BY REGION, 2019–2026 (USD MILLION)
     12.2 NORTH AMERICA
               TABLE 47 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER
               FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
               TABLE 48 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 49 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
               TABLE 50 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
               TABLE 51 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
               TABLE 53 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
               TABLE 54 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.2.1 US
                       12.2.1.1 The increasing prevalence of cancer is a key factor expected to drive market growth in the US
                                   TABLE 55 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 56 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
                                   TABLE 57 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 58 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 59 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 60 US: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.2.2 CANADA
                       12.2.2.1 The availability of various cancer screening programs in Canada is expected to drive market growth in Canada
                                   TABLE 61 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 62 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
                                   TABLE 63 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 64 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 65 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,  2019–2026 (USD MILLION)
                                   TABLE 66 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
     12.3 EUROPE
               TABLE 67 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 68 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
               TABLE 69 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
               TABLE 70 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 71 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
               TABLE 72 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
               TABLE 73 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.3.1 GERMANY
                       12.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
                                   TABLE 74 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 75 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
                                   TABLE 76 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 77 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 78 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 79 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.3.2 UK
                       12.3.2.1 Increasing number of diagnostic laboratories in the UK to propel the market growth
                                   TABLE 80 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 81 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,  2019–2026 (USD MILLION)
                                   TABLE 82 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 83 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 84 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 85 UK: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.3.3 FRANCE
                       12.3.3.1 Rising R&D expenditure in France to drive the market growth
                                   TABLE 86 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 87 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
                                   TABLE 88 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 89 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 90 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 91 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.3.4 REST OF EUROPE
                       TABLE 92 ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                       TABLE 93 ROE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
                       TABLE 94 ROE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 95 ROE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                       TABLE 96 ROE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                       TABLE 97 ROE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
     12.4 ASIA PACIFIC
               FIGURE 34 APAC: LIQUID BIOPSY MARKET SNAPSHOT
               TABLE 98 APAC: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 99 APAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
               TABLE 100 APAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
               TABLE 101 APAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 102 APAC: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
               TABLE 103 APAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
               TABLE 104 APAC: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.4.1 CHINA
                       12.4.1.1 Growing public access to advanced healthcare facilities to drive the market growth in China
                                   TABLE 105 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 106 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
                                   TABLE 107 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 108 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 109 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 110 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.4.2 JAPAN
                       12.4.2.1 Universal healthcare reimbursement policy to drive the market growth in Japan
                                   TABLE 111 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,  2019–2026 (USD MILLION)
                                   TABLE 112 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,  2019–2026 (USD MILLION)
                                   TABLE 113 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 114 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 115 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 116 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.4.3 INDIA
                       12.4.3.1 Increasing private & public investments in the country’s healthcare system is expected to drive the market growth
                                   TABLE 117 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                                   TABLE 118 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
                                   TABLE 119 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 120 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 121 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                                   TABLE 122 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
             12.4.4 REST OF ASIA PACIFIC
                       TABLE 123 ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
                       TABLE 124 ROAPAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
                       TABLE 125 ROAPAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 126 ROAPAC: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                       TABLE 127 ROAPAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
                       TABLE 128 ROAPAC: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
     12.5 REST OF THE WORLD
               TABLE 129 ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
               TABLE 130 ROW: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
               TABLE 131 ROW: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 132 ROW: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
               TABLE 133 ROW: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,  2019–2026 (USD MILLION)
               TABLE 134 ROW: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)

13 COMPETITIVE LANDSCAPE (Page No. - 161)
     13.1 OVERVIEW
     13.2 KEY PLAYER STRATEGIES
             13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE LIQUID BIOPSY MARKET
                       TABLE 135 OVERVIEW OF STRATEGIES DEPLOYED BY SOME LIQUID BIOPSY PRODUCT MANUFACTURING COMPANIES
     13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
               FIGURE 35 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE LIQUID BIOPSY MARKET
     13.4 MARKET SHARE ANALYSIS
               FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2020)
               TABLE 136 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION
     13.5 COMPANY EVALUATION QUADRANT
             13.5.1 LIST OF EVALUATED VENDORS
             13.5.2 STARS
             13.5.3 EMERGING LEADERS
             13.5.4 PERVASIVE PLAYERS
             13.5.5 PARTICIPANTS
                       FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
     13.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
             13.6.1 PROGRESSIVE COMPANIES
             13.6.2 STARTING BLOCKS
             13.6.3 RESPONSIVE COMPANIES
             13.6.4 DYNAMIC COMPANIES
                       FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
     13.7 COMPETITIVE BENCHMARKING
               FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE LIQUID BIOPSY MARKET
               TABLE 137 COMPANY PRODUCT TYPE FOOTPRINT
               TABLE 138 COMPANY GEOGRAPHICAL FOOTPRINT
     13.8 COMPETITIVE SCENARIO
             13.8.1 PRODUCT LAUNCHES AND REGULATORY APPROVALS
                       TABLE 139 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
             13.8.2 DEALS
                       TABLE 140 KEY DEALS
             13.8.3 LIQUID BIOPSY: OTHER DEVELOPMENTS
                       TABLE 141 OTHER KEY DEVELOPMENTS

14 COMPANY PROFILES (Page No. - 173)
     14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             14.1.1 QIAGEN N.V.
                       TABLE 142 QIAGEN N.V.: BUSINESS OVERVIEW
                       FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
             14.1.2 F. HOFFMANN-LA ROCHE
                       TABLE 143 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
                       FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
             14.1.3 MYRIAD GENETICS, INC.
                       TABLE 144 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
                       FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
             14.1.4 THERMO FISHER SCIENTIFIC INC.
                       TABLE 145 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                       FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
             14.1.5 GUARDANT HEALTH, INC.
                       TABLE 146 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
                       FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2020)
             14.1.6 BIO-RAD LABORATORIES
                       TABLE 147 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                       FIGURE 45 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
             14.1.7 ILLUMINA, INC.
                       TABLE 148 ILLUMINA, INC.: BUSINESS OVERVIEW
                       FIGURE 46 ILLUMINA: COMPANY SNAPSHOT (2020)
             14.1.8 EXACT SCIENCES
                       TABLE 149 EXACT SCIENCES: BUSINESS OVERVIEW
                       FIGURE 47 EXACT SCIENCES: COMPANY SNAPSHOT (2020)
             14.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
                       TABLE 150 SYSMEX INOSTICS: BUSINESS OVERVIEW
                       FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
             14.1.10 BIOCEPT, INC.
                       TABLE 151 BIOCEPT, INC.: BUSINESS OVERVIEW
                       FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2020)
             14.1.11 MDX HEALTH
                       TABLE 152 MDX HEALTH: BUSINESS OVERVIEW
                       FIGURE 50 MDX HEALTH: COMPANY SNAPSHOT (2020)
     14.2 OTHER PLAYERS
             14.2.1 NEOGENOMICS, INC.
             14.2.2 ANGLE PLC
             14.2.3 EPIGENOMICS AG
             14.2.4 MENARINI-SILICON BIOSYSTEMS
             14.2.5 VORTEX BIOSCIENCES, INC.
             14.2.6 EXOSOME DIAGNOSTICS, INC.
             14.2.7 MEDGENOME INC.
             14.2.8 AGENA BIOSCIENCE, INC.
             14.2.9 PERSONAL GENOME DIAGNOSTICS, INC.
             14.2.10 FREENOME HOLDINGS, INC.
             14.2.11 STRAND LIFE SCIENCES
             14.2.12 LUNGLIFE AI, INC.
             14.2.13 LUCENE HEALTH INC.
             14.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX (Page No. - 224)
     15.1 DISCUSSION GUIDE
     15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     15.3 AVAILABLE CUSTOMIZATIONS
     15.4 RELATED REPORTS
     15.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the liquid biopsy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Liquid Biopsy Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the liquid biopsy market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the liquid biopsy market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Liquid Biopsy Market Size: Top-Down Approach

Liquid Biopsy Market  Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global liquid biopsy market by product & service, circulating biomarkers, technology, application, clinical application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall liquid biopsy market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as product launches, regulatory approvals, expansions, agreements, partnerships, collaborations, and acquisitions in the liquid biopsy market
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Liquid biopsy market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company Profiles

  • Additional five company profiles of players operating in the liquid biopsy market.
Report Code
MD 4456
Published ON
Nov, 2021
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Liquid Biopsy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved